These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 34175498

  • 1. Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series.
    Kaminsky LW, Aukstuolis K, Petroni DH, Al-Shaikhly T.
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):481-487. PubMed ID: 34175498
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
    Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, Barete S, Canioni D, Lhermitte L, Rossignol J, Arock M, Dubreuil P, Lortholary O, Hermine O.
    J Allergy Clin Immunol Pract; 2019 Oct; 7(7):2387-2395.e3. PubMed ID: 30954641
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of idiopathic anaphylaxis with omalizumab.
    Sanchez-Valenzuela MC, Garcia-Saucedo JC, Motoa G, Carrillo-Martin I, Gonzalez-Estrada A.
    Ann Allergy Asthma Immunol; 2019 Dec; 123(6):612-613. PubMed ID: 31568858
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H, Baeck M, Stockman A, Sabato V, Grosber M, Moutschen M, Lambert J, Vandebuerie L, de Montjoye L, Rabijns H, Allewaert K, Schrijvers R.
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [Abstract] [Full Text] [Related]

  • 13. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L, Skjold T, Deleuran M, Vestergaard C.
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract] [Full Text] [Related]

  • 14. Use of omalizumab in the treatment of chronic urticaria.
    Cordeiro Moreira AS, Rosmaninho Lopes de Soares E Silva MI, Pereira Guilherme MA, da Silva Ferreira JA, Fonseca Moreira da Silva JP.
    Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis.
    Bilò MB, Corsi A, Brianzoni MF, Garritani MS, Antonicelli L.
    Ann Allergy Asthma Immunol; 2018 Aug; 121(2):249-250. PubMed ID: 29753833
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab.
    Auyeung KL, Kim BS.
    J Dermatolog Treat; 2024 Dec; 35(1):2371545. PubMed ID: 38972668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.